Latest Reports

With many aging animal and biocontainment facilities coming to the end of their useful life, renovations, modernizations, and upgrades are by far the top priorities among facility owners and operators, and greater flexibility and adaptability are the hottest issues in project and program planning. Rodents are still overwhelmingly the primary species in animal research, according to industry leaders, and most containment facilities maintain a combination of containment levels; of facilities housing a single containment level, BSL-2 is by far the most prevalent.

A new interdisciplinary medical and health sciences education building at the University of North Dakota (UND) has reinvigorated academic culture with shared resources and improved research capacity, while accommodating increased enrollment and faculty. The 325,000-sf School of Medicine and Health Sciences (SMHS) building replaces the repurposed hospital that previously housed medical education on the campus, bringing disciplines including medical lab sciences, physician assistant, occupational therapy, sports medicine, public health, and physical therapy together with medicine.

As scientific research increasingly moves toward a greater use of data, so too is the animal cage technology being introduced and developed by major manufacturers. Innovations designed to improve animal life, reduce costs, and enhance research are happening at the cage level, with technology allowing for control of conditions within individual housing units and data collection of cage-level variables.

Penn Medicine and Novartis have joined forces to create the new Center for Advanced Cellular Therapies (CACT), located atop the Henry Jordan Medical Education Center at the Perelman School of Medicine. Dedicated to finding more effective treatments for cancer using personalized medicine, this first-of-its-kind facility forms the epicenter for research using chimeric antigen receptor (CAR) technology, which enables a patient’s T cells to be removed, reprogrammed, and re-infused into the patient, where they can “hunt” and destroy cancer cells.

After a one-year delay, Congress has passed the 21st Century Cures Act, which includes new funding totaling $4.8 billion for the National Institutes of Health (NIH), $500 million for the Food and Drug Administration (FDA) to bring novel drug therapies and medical devices to market more quickly, and $1 billion to fight the growing opioid crisis. The NIH funding includes $1.8 billion for Vice President Joseph Biden’s “Cancer Moonshot,” $1.6 billion for President Obama’s BRAIN initiative, and additional money earmarked for precision medicine. The Cures Act funding is separate from, and in addition to, annual NIH budget increases. It comes on the heals of a $2 billion increase in NIH funding last year, the largest increase in a decade. If the trend continues, it could result in a need for additional research infrastructure in the form of renovations and new construction.